Photo: Courtesy of Teva
Teva announced yesterday that the Federal Trade Commission (FTC) has accepted its proposed $40.5 billion buyout of Allergan’s generics business after the Isreal-based company agreed to sell nearly 80 products to address competition concerns.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Teva, Allergan, FTC, anticompetitive, generics, acquisition